Processa Pharmaceuticals, Inc. Finance Lease, Principal Payments
Processa Pharmaceuticals, Inc. (PCSA) reported Finance Lease, Principal Payments of $6.60 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $3.75K, a 161.10% increase year-over-year.
- Processa Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-06-30 was $1.31K, a 6.54% decline year-over-year.
- Processa Pharmaceuticals, Inc. finance lease, principal payments for the quarter ending 2025-03-31 was $1.54K, a 71.62% increase year-over-year.
- Processa Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2025 was $6.60K, a 26.91% increase from fiscal 2024.
- Processa Pharmaceuticals, Inc. finance lease, principal payments for fiscal 2024 was $5.20K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.75K derived: sum of 2 quarters · filed 2026-03-18 | $5.07K derived: sum of 3 quarters · filed 2026-08-14 | $6.60K 10-K · filed 2026-03-18 |
| 2025-09-30 | $3.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.07K derived: sum of 2 quarters · filed 2026-08-14 | $6.60K 10-Q · filed 2025-11-06 | $8.07K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.85K 10-Q · filed 2026-08-14 | $4.31K derived: sum of 3 quarters · filed 2026-08-14 | $5.75K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.54K 10-Q · filed 2026-05-07 | $3.00K derived: sum of 2 quarters · filed 2026-05-07 | $4.44K derived: sum of 3 quarters · filed 2026-05-07 | $5.84K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.90K derived: sum of 2 quarters · filed 2026-03-18 | $4.31K derived: sum of 3 quarters · filed 2026-03-18 | $5.20K 10-K · filed 2026-03-18 |
| 2024-09-30 | $1.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.84K derived: sum of 2 quarters · filed 2025-11-06 | $3.74K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.30K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $895.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |